Archive for the 'Oncology' Category

Fermented Extract of Noni Fruit to aid in Fighting Cancer

According to a report published by Oncology Reports, a fermented extract of the Noni fruit ,which is commonly found in Southeast Asia and the Pacific, could help the immune system attack cancer cells, and may provide long-term cancer protection. The Noni fruit, scientifically known as Morinda citrifolia, has been used in Polynesian folk medicine for more than 2,000 years.

The Noni Fruit. Photo from Flickr.

The Noni Fruit. Photo from Flickr.

The report, published by lead author Yanzhang Wei, PhD, Professor in the Department of Biological Sciences at Clemson University, and Assistant Director of the Clemson University Biomedical Institute, mentioned that fermented Noni may contain some bacterial and/or fungal materials, which may have the potential to engage the innate immune system through toll-like receptors (TLRs). The innate immune system is the body’s first line of defense against infection, and toll-like receptors are important proteins that help trigger this immune response.

Dr. Wei and his colleagues evaluated the use of a fermented liquid extract from the Noni fruit (fermented Noni exudate, or fNE) to prevent and treat cancer.

For the prevention study, female mice were injected with one of three substances: fNE, a phosphate-balanced solution (PBS, which is similar to saline solution), or lipopolysaccharides (LPS, a natural toxin found in bacteria and in fermented Noni juice) for three days. Then the researchers injected the mice with lung cancer and sarcoma cells. Meanwhile for the treatment study, the mice were first injected with the cancer cells, and then treated with three doses of fNE, LPS, or PBS.

The results of the prevention study was that after the mice were injected with fNE, they developed greater numbers of immune cells such as granulocytes (a type of white blood cell) and natural killer (NK) cells, indicating that fNE had stimulated their immune system.

In the treatment study, a month after receiving fNE for sarcoma treatment or prevention, more than 85 percent of the mice were not only alive, but also cancer-free. For lung cancer tumor cells, fNE also was effective, although the tumor prevention rate was slightly lower (62 percent). Meanwhile, all of the mice that received PBS or LPS died.

The study also showed that fNE not only warded off cancer immediately—it also provided long-term protection. When the mice that had received fNE were injected with sarcoma tumor cells a second time, 15 out of 16 of them rejected the tumors.

Similar experiments were conducted with nude mice (a laboratory mouse from a strain with a genetic mutation that causes a deteriorated or absent thymus gland, resulting in an inhibited immune system due to a greatly reduced number of T cells) and beige mice (strain of mice that are immune deficient). All of the nude mice eventually died, but fNE was able to prolong their lives. The beige mice died within 20 days of receiving the cancer cells, which the authors say was because they lacked functional NK cells. These cells of the innate immune system were responsible for the majority of the response to fNE treatment.

“These results indicate that the activation of the first line of defense of the innate immune system is absolutely necessary to kill the tumor cells,” the authors write. However, the innate immune system alone is not enough to wipe out tumors. It must work in conjunction with the adaptive immune system—the part of the immune system that protects against re-exposure to the same harmful substances. fNE appears to activate both aspects of the immune system to destroy cancers.

Future studies will help researchers gain a better understanding of how fNE stimulates the immune system, and determine whether it might be effective against other types of cancers. For now, the fruit extract shows great promise as a cancer-fighting agent. “I feel positive that fNE or its derivatives will provide useful new options for cancer, especially for cancer prevention,” Dr. Wei says.

Chang Gung Memorial Hospital first in Taiwan to use Varian RapidArc(TM)

One of the largest hospital groups in Taiwan, Chang Gung Memorial Hospital in Linkou has begun treatments using a new, faster form of radiotherapy that potentially enables doctors to improve outcomes while extending modern care to more patients. According to the hospital, a 50-year-old male patient with head and neck cancer was the first patient in Taiwan to be treated using RapidArc(TM) technology from Varian Medical Systems.

Dr. Ji-Hong Hong M.D., director of the hospital’s department of radiation oncology, carried out the pioneering treatment conducted the procedure in just two and half minutes using two arcs, or rotations, of the machine around the patient. This is in comparison to conventional IMRT (intensity modulated radiotherapy) treatments, which would have taken 8 to 10 minutes, according to the doctor.

Varian's RapidArc(TM) System. Picture from Varian Medical Systems.

Varian's RapidArc(TM) System. Picture from Varian Medical Systems.

“Along with prostate cancer, head and neck tumors are the most common cancer treated with radiotherapy in Taiwan and we feel patients with these forms of cancer will be the main beneficiaries of RapidArc,” says Dr. Hong. “The first patient received radiotherapy using RapidArc for tumors at the base of his tongue and right neck node metastasis. It was quite a complex treatment but delivery was very quick and efficient, with reduced dose to healthy tissue. We were extremely happy with the performance.”

Chang Gung Memorial Hospital’s department of radiation oncology treats up to 300 patients each day and sees between 2,600 and 3,000 new cancer patients each year. Such a heavy workload results in mounting waiting lists and Dr. Hong believes RapidArc is a good way to relieve pressure on these waiting lists without compromising the quality of the treatments offered.

Polartechnics looks to Shareholders to Raise Funds

Polartechnics, the Australian manufacturer of diagnostic kits for cervical cancer and melanoma, announced yesterday that it will launch a Share Purchase Plan (SPP) in February 2009 to present shareholders of the company, entitling them to acquire additional parcels of ordinary fully paid shares in the company. Under the plan, each eligible shareholder, irrespective of their current size of shares held, will be to purchase up to A$5,00o worth of new Polartechnics ordinary shares. Issue price for shares offered under the scheme will be A$0.11 per share, representing a 19.94% discount to the average traded market price recorded between 16th to 20th February 2009.

“We have overcome the challenges from scaling up our manufacturing to full production capacity putting us in a strong position to meet our sales forecasts for TruScreen. Additionally we have signed major distribution agreements for our new self-sampling products,” said Polartechnics Chairman, Robert Hunter.

According to the press release from the company, funds from the SPP will be funneled as working capital and for the continued expansion that will help the company distribute their products in a greater number of markets.

China Medical Technology sells HIFU unit to Major Shareholder

It was reported that China Medical Technologies is selling its High Intensity Focused Ultrasound (HIFU) tumor therapy system business to Chengxuan International, its major shareholder for $53.5 million in cash. Chengxuan is owned by Mr. Xiaodong Wu, the Chairman and Chief Executive Officer of the China Medical Technologies.

China Medical Technologies HIFU System. Picture from China Medical Technologies.

China Medical Technologies' HIFU System. Picture from China Medical Technologies.

According to China Medical, the HIFU business is said to differ from the company’s current focus in the development of advanced IVD businesses. The business unit, which primarily sells high-end HIFU equipment, is seasonal and volatile and required large capital infusions required to obtain US and EU regulatory approvals. In addition, China Medical has also cited the current conditions in the global financial markets for selling its HIFU business.

The proceeds from the sale will go towards research and development of China Medical’s existing advanced in-vitro diagnostics (IVD) businesses so as to generate recurring and increasing revenues. China Medical Technologies IVD offerings includes the Enhanced Chemiluminescence Immunoassay (ECLIA) System and the Fluorescent in situ Hybridization (FISH) Probes and FISH Imaging Analysis System.
Mr Sam Tsang, Director and CFO, China Medical Technologies said that the company will now be completely focused on expanding our leading position in the advanced IVD sector in China. He also mentioned that this transaction will strengthen China Medical’s financial position, further enhancing the company’s ability to capitalize on the opportunities within the molecular diagnostics industry in China.
On a side note, the company also reported reported revenues of RMB290.5 million (US$42.8 million) for 2Q FY2008, representing a 35.2% increase from the corresponding period of FY2007. Net income, meanwhile was RMB117.7 million (US$17.3 million) for 2Q FY2008, representing a 52.1% increase from the corresponding period of FY2007, as gross margin increased to 73.2% for 2Q FY2008 from 61.5% for the corresponding period of FY2007. China Medical Technologies attributed the increase in gross margin to the change in revenue mix where a substantial portion of revenues was generated from recurring sales of higher margin ECLIA reagent kits and FISH probes.

KAIST opens Cell Bench Research Center

Korea Advanced Institute of Science and Technology (KAIST) officially opens a new Cell Bench Research Center on its campus within the city of Daejeon. The research center marked the start of a joint project with Samsung Electric Co. and Samsung Medical Center. A total of about 100 people from the three organizations, including KAIST President Nam-Pyo Suh, Samsung Electric’s Chief Technology Officer (CTO) Byung-Cheon Koh and Samsung Medical Center Vice President Hyo-Geun Lim, were present for the official opening ceremony.

In the press release by KAIST, the center will start work on the development of individually-tailored anti-cancer medicine using bio-inspired cell chips and technologies for clinical applications. KAIST President Nam-Pyo Suh mentioned on the opening ceremony that he expected the center will open a new path for the science and technology community and the industry to combine their strengths and develop innovative anti-cancer therapeutics through the involvement of the best professionals within academia, the electronic industry and the medical community.

The opening of the research center also marks Samsung Electric’s move into biomedical research from its usual focus of the information technologies industry. Samsung Electric CTO Byung-Cheon Koh commented that he hopes the cooperation with KAIST and Samsung Medical Center will allow the development of a simple and efficient cure for cancer patients.

Initial research work within the research center is to focus on the development of cell chips for lung cancer, one of the primary causes of death for Koreans.

High Ion Beams Therapy for Deep Seated Tumors made Possible in China

Chinese nuclear physicists have completed the development of a oncology treatment to destroy malignant tumors more than 2.1 cm below the skin surface through the use of heavy ion beams. This research accompishment follows up on the success by the same group of scientists made in January when they managed to use heavy ion beams to treat tumors 2.1 cm or less below the body surface.

Zhan Wenlong, the country’s leading nuclear physicist, said that, “Compared with light ion beams, such as gamma rays and X-rays used in traditional radiotherapies, heavy ion beams are considered the most effective, so far, in accurately moderating the amount of radiation and minimizing the damage done to healthy cells.”

The new treatment method will use stronger heavy ion beams that could reach up to 400 mega electron volts (MeV) at their highest level allowing beams to travel farther into the human body to kill deeper seated tumors. Research in this area was made possible with the Heavy Ion Research Facility in Lanzhou – Cooler Storage Ring (HIRFL-CSR), a 300 million Yuan (about US$ 44 million) national science project built in the northwest Gansu Province capital. One of the researcher mentioned that internally developed heavy ion beams used in the January tests were 100 MeV, which limited the treatment to shallow tumors.

Working at the CAS Institute of Modern Physics, Zhan and his research team have come up with a wide spectrum of heavy ion beams, ranging from 80 to 400 MeV, allowing treatment to be conducted on both shallow and deeper seated tumors. The researchers will be refining the system software so as to enable clinical trials using this new technology to proceed in the near future.

With this achievement, China became only the fourth country in the world to successfully use heavy ions for cancer therapy, after Germany, Japan and the United States.

HealthLinx and ARL Pathology rolls out Early Stage Test for Ovarian Cancer

HealthLinx, an Australian emerging biomarker and diagnostic company will work with along with Analytical Reference Laboratories Pty Ltd (ARL Pathology), to start the commercial launch of OvPlex, billed as the world’s first early stage detection test for ovarian cancer.

OvPlex will initially be made available through ARL Pathology who are based in Melbourne, Victoria and gradually expanded to other states within Australia. According to the information on its website, OvPlex is a diagnotic test that utilizes 5 biomarkers within the blood to detect ovarian cancer in women. In addition, it adds that research documentation shows that future trends in oncology diagnostics will incorporate more than a single marker to increase sensitivity and specificity for diagnosing a particular disease.

HealthLinx also mentions in its press release that up to 1,500 Australian women are diagnosed with ovarian cancer annually and more than 800 of these cases will prove fatal. Globally, 230,000 cases are diagnosed every year and more than 142,000 deaths would result from ovarian cancer.

Professor Greg Rice, Chairman of HealthLinx, mentions that the high death count from ovarian cancer makes it one of the most fatal amongst reproductive tract cancers and this results up to 75% of female patients being diagnosed with ovarian cancer only when they are at the later stages. As such, survival rates within 5 years from diagnosis for such cases are in the range of 20-30%. Early stage detection would boost the survival rates within 5 years to 80%.

Mr Nick Gatsios, Managing Director of HealthLinx, summarized this development by saying, “This is a medical milestone in women’s health. It changes HealthLinx into a diagnostic developer and product sales company.”

China Medical Technology purchases HPV Biosensor Chip System

Beijing-based and NASDAQ-listed China Medical Technologies will buy a Human Papillomavirus (HPV) detection system as well as a Surface Plasmon Resonance (SPR) based analysis system for a total consideration of US$ 345 million in cash installments from Molecular Diagnostics Technologies.

The press release from China Medical states that the HPV-DNA biosensor chip is a label-free DNA chip for the diagnosis of HPV infection and genotyping of HPV. The DNA chip will be able to detect up to 24 common strains of HPV, including being able to detect those strains that can cause genital warts and cervical cancer. Meanwhile, the SPR system is a leading biosensor technology used to analyze the data on the DNA chip, and have been applied in various clinical diagnostic purposes, such as the detection of biomarkers related to infectious diseases, cancers, cardiovascular and immune system disorders. By using the HPV-DNA Biosensor Chip to detect presence of HPV, and combining this with an analysis using the SPR system, scanning of patients can be done more effectively and efficiently within a shorter time span.

The company said about 50 million HPV-related gynecological tests are done in China every year, and about 120 million women should receive cervical cancer tests. It is also expected that the purchased technology will help to generate US$ 23.6 -26.5 million of revenues for China Medical Technologies each year starting from 2009, and that gross profit margin will stand at an estimated 80 percent. The deal is expected to be closed in December 2008 or January 2009, with the final installment payment to be made a year later.

Japanese Researchers develops Carbon Nanohorn to combat Cancer

Researchers at Japan’s National Institute of Advanced Industrial Science and Technology (AIST) and Fujita Health University announced on Tuesday that they had succeded in virtually destroying a tumor in a mouse after administering it with carbon nanohorn filled with medicine used in photodynamic therapy for cancer.

The researchers said that the finding will be applied in the development of a new cancer medicine using carbon nanohorn – which is as tiny as 1/10,000th of a hair in thickness.

According to the researchers, nanohorn itself absorbs laser beam and emits high heat, generating a synergistic effect of photodynamic therapy and thermotherapy in destroying cancer cells. Photodynamic therapy is intended to destroy cancer cells by emitting a laser beam to a light-sensitive substance gathered around the area of the disease, prompting it to produce active oxygen that kills cancer cells.

The researchers utilizes the photosensitizer, zinc phthalocyanine into the nanohorn measuring 2 to 5 nanometers in thickness and 40 to 50 nanometers in length. From there, they injected the nanohorn into the tumor of a mouse and emitted a laser beam at the nanohorn for 15 minutes every day. Researchers noticed that the tumour disappeared after a period of 10 days.

By absorbing light, black carbon nanohorn could generate a rise in temperatures to about 40 degrees Celsius, thereby generating a thermotherapy effect, which would have a secondary effect on the destruction of cancer cells.

Hoewever, Masako Yudasaka, head of the research team at the AIST, mentioned, “Since nanohorn tends to remain in a body for a long time, we need to examine its long-term toxicity and how to discharge it from a body.” The researchers made the announcement in the online edition of a bulletin for the National Academy of Sciences of the United States on Tuesday.

Singapore Researchers find Key Gatekeeper Gene that play Key Role in Colon Cancer

A team of researchers at the NUS Yong Loo Lin School of Medicine and Institute of Molecular and Cell Biology (IMCB), Agency for Science, Technology and Research (A*STAR) have discovered a new gatekeeper gene. A gatekeeper determines whether or not the disease begins in the human body – a crucial step in developing both an early diagnostic test as well as a therapeutic target. The absence of this gene paves the way for the growth and development of colon cancer.
In an earlier research breakthrough, the same team of researchers led by Professor Yoshiaki Ito, NUS Yong Loo Lin Professor in Medical Oncology and Principal Investigator of the Institute of Molecular and Cell Biology, A*STAR had reported that RUNX3 is a major tumor suppressor of gastric cancer. The research had also shown that RUNX3 plays a key role in breast cancer and bladder cancer, among others.
This latest finding is reported in the September issue of Cancer Cell, a top-tier biomedical research journal. In it, Professor Ito describes how he and his team found that inactivation of RUNX3 causes full-blown colon cancer to develop. For more on the press release, go here

Next Page »